OOIR: Observatory of International Research

Papers

(The H4-Index of British Journal of Haematology is 38. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
e‐Posters	145
Graham Serjeant, Sickle Cell, Jamaica and Beyond: A Life, Ian Randle Publishers (Kingston and Miami), 2021	122
Don't forget cord blood in non‐remission acute myeloid leukaemia!	121
Issue Information	88
Issue Information	85
Association of biomarkers of endothelial function, coagulation activation and kidney injury with persistent albuminuria in sickle cell anaemia	81
Correction to “Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients”	79
	76
Clinical perspectives on post‐induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation	75
Issue Information	75
Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data	72
MYC‐induced cytidine metabolism regulates survival and drug resistance via cGas‐STING pathway in mantle cell lymphoma	67
Erythrophagocytosis in a patient with myelodysplastic syndrome with excess blasts‐1 with isolated del(6q)	65
Haematopoietic stem cell mobilisation followed by high‐dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma	62
Applying current smouldering myeloma risk models to a UK single‐centre cohort and clinical features at progression	61
Using the in vitro drug sensitivity test to identify candidate treatments for transient abnormal myelopoiesis	56
ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non‐myeloablative conditioning	55
The impact of COVID‐19 vaccination on patients with a history of heparin‐induced thrombocytopenia	54
Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID‐19 vaccine in haemato‐oncological patients with no antibody response	53
The role of genetics in refractory immune thrombocytopenia	53
Stratified management based on surface antibody for the prevention of hepatitis B virus reactivation in lymphoma patients	52
Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline	50
Immune thrombocytopenia (ITP) in pregnancy	49
The significance of mixed chimaerism and cell lineage chimaerism monitoring in paediatric patients post haematopoietic stem cell transplant	49
Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma – A study from the Danish Lymphoma Registry	48

Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts	48
Myelodysplastic syndrome associated‐haemophagocytic lymphohistiocytosis: A retrospective study of 15 cases in a single centre	47
Functional impairment of erythropoiesis in Congenital Dyserythropoietic Anaemia type I arises at the progenitor level	46
Antibody response to a third SARS‐CoV‐2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation	46
Immunophenotypic clustering in paediatric acute myeloid leukaemia	46
A 4‐gene prognostic index for enhancing acute myeloid leukaemia survival prediction	44
Non‐pharmacological supportive‐care interventions in acute myeloid leukaemia: a review of randomised controlled trials	42
Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L‐ASP: A retrospective analysis with an ASP‐based protocol in adult patients with acute lympho	39
Venetoclax ramp‐up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study	39
Characterisation of two tumour cell populations in the small cell variant of anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma	38
Long‐term outcome after allogeneic stem cell transplantation for GATA2 deficiency: An analysis of 67 adults and children from France and Belgium	38
Use of dipyridamole is associated with lower risk of lymphoid neoplasms: a propensity score‐matched cohort study	38
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia	38